Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism-Reference-Cited by-同舟云学术

Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism

Published:2016-03-30 Issue:12 Volume:46 Page:1234-1246
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Uchida Yoshihito¹,Kouyama Jun-ichi¹,Naiki Kayoko¹,Sugawara Kayoko¹,Inao Mie¹,Imai Yukinori¹,Nakayama Nobuaki¹,Mochida Satoshi¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Faculty of Medicine; Saitama Medical University; Moroyama Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12673/fullpdf

Reference17 articles.

1. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir;Karino;J Hepatol,2013

2. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options;Suzuki;J Hepatol,2013

3. Daclatasvir plus asnaprevir for chronic HCV genotype 1b infection;Kumada;Hepatology,2014

4. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors;Uchida;PLoS One,2014

5. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing;Uchida;J Gastroenterol,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region;South of Russia: ecology, development;2024-04-07

2. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection;Clinical Journal of Gastroenterology;2020-07-12

3. Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus;Hepatology Research;2020-04

4. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all‐oral direct antiviral therapy;Hepatology Research;2020-04

5. NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors;Seminars in Liver Disease;2019-12-13